Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEC-FLAG-Ida/RIC for High-Risk Myeloid Malignancies
NCT06928662Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and 2 more, sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Non-relapse mortality at Day 100 and Disease-free survival at 1 year. Started Sep 2025; status: recruiting.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute undifferentiated leukemia (AUL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT06928662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06928662.